Clinical Trial Update: Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

View source ↗

Summary

Clinical trial update reporting outcomes from a comparison of XT versus XEC adjuvant chemotherapy in patients with HER2-negative luminal B breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• XEC
• XT

Snippet

Sponsor: Guangdong Academy of Medical Sciences | Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Status: UNKNOWN